ABSTRACT NUMBER: ESOC2026A1666 BUILDING THE FUTURE OF PRECISION MEDICINE IN STROKE MANAGEMENT: DESIGN AND COHORT PROFILES OF THE GENESIS-K STUDY

Abstract Background and aims Given that current stroke guidelines do not fully reflect individual variability across highly heterogeneous phenotypes, the GENESIS-K project aims to build a multi-dimensional cohort to facilitate personalized stroke care through pharmacogenomics. Methods The study enrolls clinical and genomic data from ≥10,000 patients leveraging a nationwide, multicenter prospective stroke registry. Enrollment occurs via random sampling or investigator selection (e.g. antithrombotic failure). Genotyping uses the Infinium Asian Screening Array, with additional pharmacogene variants. Results for key pharmacogenes (clopidogrel, statin, warfarin) and important non-pharmacogenes (RNF213, NOTCH3, APOE) are reported to physicians. Education of physicians for interpretation and clinical implementation of genomic results has been conducted regularly. Integration of clinical, genomic, neuroimage, and long-term outcome databases provide a robust platform for genome-wide association studies and development of polygenic risk score to investigate stroke incidence and prognosis, and individual medication response. Results During Oct 2023-Nov 2025, 5,328 patients (99% ischemic stroke) were enrolled across 30 centers (57% by random allocation). Key variant frequencies (CYP2C19, SLCO1B1, RNF213 and NOTCH3) were higher than those in the UK Biobank East Asian population. A physician survey indicated ~80% utilization of genomic reports, particularly for clopidogrel prescribing. Conclusions The GENESIS-K study establishes a nationwide multi-faceted stroke cohort, laying the foundation for implementing precision medicine in stroke management. Conflict of interest This research was supported by a grant of the Korea Health Technology R&D Project (grant number: RS-2024-12345678), and the Korea Health Technology R&D Project (grant number: HI22C0454) through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea. The funding sources did not participate in any part of the study, from conception to article preparation.

Authors

Institutions

Publication Details

Journal
European Stroke Journal
Published
2026-05-01
DOI
https://doi.org/10.1093/esj/aakag023.789
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABSTRACT NUMBER: ESOC2026A1666 BUILDING THE FUTURE OF PRECISION MEDICINE IN STROKE MANAGEMENT: DESIGN AND COHORT PROFILES OF THE GENESIS-K STUDY

J Y Park, K N Lee, Jay Chol Choi, B H Lee et al.
European Stroke Journal
Antiplatelet Therapy and Cardiovascular Diseases
article

ABSTRACT NUMBER: ESOC2026A1666 BUILDING THE FUTURE OF PRECISION MEDICINE IN STROKE MANAGEMENT: DESIGN AND COHORT PROFILES OF THE GENESIS-K STUDY

J Y Park, K N Lee, Jay Chol Choi, B H Lee, Jonguk Kim, Hee-Joon Bae, Jeong-Yoon Lee, Joohon Sung, Do Yeon Kim, Juneyoung Lee, Minwoo Lee
article en

Abstract

Abstract Background and aims Given that current stroke guidelines do not fully reflect individual variability across highly heterogeneous phenotypes, the GENESIS-K project aims to build a multi-dimensional cohort to facilitate personalized stroke care through pharmacogenomics. Methods The study enrolls clinical and genomic data from ≥10,000 patients leveraging a nationwide, multicenter prospective stroke registry. Enrollment occurs via random sampling or investigator selection (e.g. antithrombotic failure). Genotyping uses the Infinium Asian Screening Array, with additional pharmacogene variants. Results for key pharmacogenes (clopidogrel, statin, warfarin) and important non-pharmacogenes (RNF213, NOTCH3, APOE) are reported to physicians. Education of physicians for interpretation and clinical implementation of genomic results has been conducted regularly. Integration of clinical, genomic, neuroimage, and long-term outcome databases provide a robust platform for genome-wide association studies and development of polygenic risk score to investigate stroke incidence and prognosis, and individual medication response. Results During Oct 2023-Nov 2025, 5,328 patients (99% ischemic stroke) were enrolled across 30 centers (57% by random allocation). Key variant frequencies (CYP2C19, SLCO1B1, RNF213 and NOTCH3) were higher than those in the UK Biobank East Asian population. A physician survey indicated ~80% utilization of genomic reports, particularly for clopidogrel prescribing. Conclusions The GENESIS-K study establishes a nationwide multi-faceted stroke cohort, laying the foundation for implementing precision medicine in stroke management. Conflict of interest This research was supported by a grant of the Korea Health Technology R&D Project (grant number: RS-2024-12345678), and the Korea Health Technology R&D Project (grant number: HI22C0454) through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea. The funding sources did not participate in any part of the study, from conception to article preparation.

European Stroke JournalVol. 11(Supplement_1)
Seoul National University (KR), Eulji University (KR), Korea University Medical Center (KR), Soonchunhyang University Hospital Seoul (KR), Seoul National University Bundang Hospital (KR), Hallym University Sacred Heart Hospital (KR), Korea University (JP), Jeju National University Hospital (KR)
Openalex Percentile: Top 8%
Antiplatelet Therapy and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.